AbbVie Inc. closed 14.67% below its 52-week high of $207.32, which the company achieved on October 31st.

Investors in AbbVie Inc. ABBV need to pay close attention to the stock based on moves in the options market lately. That is because the Feb. 21, 2025 $115.00 Call had some of the highest implied ...

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ...

We recently published a list of 11 Best Bear Market Stocks To Invest In Now. In this article, we are going to take a look at ...

William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a price ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $170.67 which represents a slight increase of $1.47 or 0.87% from the prior close of $169.2. The stock opened at $170.46 and touched a ...

AbbVie Inc. closed $31.77 below its 52-week high ($207.32), which the company reached on October 31st.

Research analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a note ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $171.56 which represents a decrease of $-2.14 or -1.23% from the prior close of $173.7. The stock opened at $172.88 and touched a ...

AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular ...